Objective: This study was to assess the efficacy and safety of Xiyanping plus azithromycin in curing the mycoplasma pneumonia. Method: Some Chinese-english databases including Pubmed

Embase

CENTRAL

CBM

CNKI

VIP and wanfang were searched to collect the Randomized controlled trials (RCTs). After two reviewers have selected trials independently and assessed methodologically quality by Jadad scale

valid data would be extracted to make a Meta-analysis. Result: A total of 11 RCTs were brought in

including 942 cases. Meta-analysis showed that

the treatment group of Xiyanping combined with azithromycin has advantages on the total effective rate [OR=4.08

95%CI(2.14

7.78)]

cooling time [MD=-1.17

95%CI(-1.49

-0.85)]

cough-disappear time [MD=-2.04

95%CI(-2.63

-1.44)]

healing time [MD=-2.60

95%CI(-3.02

-2.16)]

rales disappeared time [MD=-1.52

95%CI(-2.81

-0.22)] and the reduction of occurrence of adverse reactions [OR=0.48

95%CI(0.30

0.77)]. However

both of the groups didnt show significant difference on X-ray-disappear time [MD=-7.55

95%CI(-17.80

2.70)]. Conclusion: We concluded that the efficacy of treatment group which combine Xiyanping with azithromycin is superior to azithromycin alone.